Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trevena, a US based developer of GPCR biased ligand drugs, has signed a five year U01 cooperative agreement with an aim to develop biased ligand to the delta opioid receptor targeting major depressive disorder.
Subscribe to our email newsletter
The Trevena award includes $460,000 in direct funding, and access to millions of dollars worth of contracted research services.
The NIH has awarded this contract through its Blueprint Neurotherapeutics Network, which aims to develop new drugs for disorders of the central nervous system.
The Blueprint will fund both activities at Trevena, leverage resources at the 15 agency institutes and centers in the Network, and involve work by consultants and contractors.